We have commitments against existing development activities and capital commitments relating to the purchase of

isotope raw materials from a vendor over a three year period. R&D commitments are estimated based on the contractual

obligations included within agreements entered into by us, to the extent that a work order has been executed with the

Certain of our supply agreements contain minimum purchase commitments in certain situations, the amount and timing of

which are not known. Additionally, we enter into contracts in the normal course of business with clinical trial sites and

clinical supply manufacturers and with vendors for preclinical studies and clinical trials, research supplies and other

services and drugs for operating purposes. These contracts generally provide for termination after a notice period, and,

We have entered into collaboration arrangements, including in-licensing arrangements with various companies. Such

collaboration agreements may require us to make payments on achievement of stages of development, launch or

revenue milestones and may include variable payments that are based on unit sales or profit (e.g., royalty and profit

share payments). The amount of variable payments under the arrangements are inherently uncertain and difficult to

predict, given the direct link to future sales, profit levels and the range of outcomes. These payments are not included in

At December 31, 2025 and at the date of these financial statements, the Group had capital commitments relating to the

construction of the Brussels South manufacturing facility and the purchase of isotope raw materials from a vendor over a